Names & Terms You Will Hear
Plain-language meanings for the terms your care team may use.
| Term | Meaning |
|---|---|
| Flecainide | Generic name. The brand name was Tambocor. |
| Propafenone | Generic name. Brand names include Rythmol and Rythmol SR. |
| Class 1C antiarrhythmic | The drug family both belong to. They slow the speed of the heart's electrical signal. |
| Structural heart disease | A heart that is not normally built or does not pump normally. Prior heart attack, a weak pump, significant coronary blockages, or thickened or scarred muscle. |
| Pill-in-the-pocket | Carrying a single dose and taking it only when an episode starts, instead of taking a pill every day. |
| Atrial flutter with 1:1 conduction | An uncommon but dangerous effect where the lower chambers follow the upper chambers beat for beat, sending the heart rate very high. |
| AV nodal blocker | A rate-slowing medicine, usually a beta-blocker or a calcium channel blocker, taken alongside to prevent that. |
Never take the rhythm pill by itself. Flecainide and propafenone are always paired with a rate-slowing medicine, usually a beta-blocker or a calcium channel blocker. Taking the rhythm pill alone is what allows a very fast heart rate. If you have run out of the rate-slowing pill, call us before taking a dose.
What Is Flecainide and Propafenone?
- Flecainide and propafenone are two closely related pills that help keep the heart in a normal rhythm.
- They are used most often for atrial fibrillation, and sometimes for other fast rhythms from the upper chambers.
- They work by slowing the speed of the electrical signal moving through the heart muscle, which makes it harder for a chaotic rhythm to sustain itself.
- They can be taken every day, or carried and taken only when an episode starts. That second approach is called pill-in-the-pocket.
- They are a good choice for many people, but only when the heart is structurally normal.
- That one condition is the most important thing on this page, and it is why you had an echocardiogram and often a stress test before starting.
| Feature | Flecainide | Propafenone |
|---|---|---|
| Usual schedule | Twice a day | Two or three times a day, or a long-acting form twice a day |
| Common nuisance effect | Dizziness, blurred vision | Metallic or bitter taste |
| Mild beta-blocking effect | No | Yes, so more caution with asthma |
| Needs a rate-slowing pill | Yes | Yes |
| Structurally normal heart required | Yes | Yes |
Why It Matters
- For someone with a structurally normal heart, these drugs are effective and usually well tolerated.
- The pill-in-the-pocket option means some people take no daily rhythm medicine at all, and treat only the episodes they actually have.
- The structural-heart restriction comes from a study called CAST, published in 1991.
- CAST gave flecainide to people who had survived a heart attack and had a weakened pump. More of them died than those on placebo. The trial was stopped early.
- That result reshaped how these drugs are used, and it still stands as the reason for the restriction.
- Researchers are now re-examining whether the restriction was drawn too broadly for some patients. That work is ongoing and has not changed standard practice.
What the CAST Trial Actually Showed
- CAST stands for the Cardiac Arrhythmia Suppression Trial. It was published in 1991.
- It enrolled people who had survived a heart attack and had extra beats from the lower chambers.
- The idea was reasonable: suppress the extra beats and prevent sudden death.
- The result was the opposite. More people died on flecainide than on placebo, and the trial was stopped early.
- The likely reason is that in a heart with scar and reduced blood flow, slowing the electrical signal creates conditions for a dangerous rhythm.
- This is why the question is never just whether the drug works, but whether your heart is the kind of heart it was safe in.
- Newer work is asking whether the restriction was applied too broadly to some patients. That is a live research question, not current practice.
Risk Factors
Knowing your personal risks helps your care team take extra precautions.
| Risk Factor | Why It Increases Risk |
|---|---|
| Prior heart attack | The exact group studied in CAST, where these drugs increased the risk of death. This is a firm reason to use something else. |
| A weak heart pump | A reduced ejection fraction puts you in the group CAST identified as being at risk. |
| Significant coronary artery disease | Narrowed heart arteries mean parts of the muscle may not get enough blood, which is the setting where these drugs can trigger a dangerous rhythm. |
| Thickened or scarred heart muscle | Cardiomyopathy of any kind changes how the electrical signal travels and raises the risk. |
| A history of atrial flutter | These drugs can convert fibrillation into flutter, which is the setting for the 1:1 conduction problem. |
| Not taking the rate-slowing pill | The beta-blocker or calcium channel blocker is not optional. It is what prevents the fast 1:1 conduction. |
| Kidney or liver problems | Both drugs are cleared by the body through these organs. Reduced function means higher drug levels. |
Treatment Options
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
- For daily use, take the pill at the same times every day, usually twice a day.
- You will almost always be given a rate-slowing pill to take alongside it, most often a beta-blocker or a calcium channel blocker.
- For pill-in-the-pocket, take the rate-slowing pill first, wait about 30 minutes, then take the single rhythm dose.
- The pill-in-the-pocket dose is based on your weight, and your cardiologist gives you the exact number. Do not guess and do not adjust it yourself.
- Your first ever pill-in-the-pocket dose is taken somewhere you can be monitored, not at home.
- After an episode you treat this way, sit or lie down and rest for several hours. Do not drive.
- You will have periodic ECGs to make sure the electrical signal is not slowing too much.
Using It as a Pill-in-the-Pocket
- This approach suits people whose episodes are occasional, recognizable, and not dangerous when they happen.
- You carry a single dose and use it only when an episode starts.
- The rate-slowing pill goes first, then roughly a 30-minute gap, then the single rhythm dose.
- The dose depends on your body weight, and your cardiologist gives you the exact number in writing.
- Your first ever dose is supervised, so we can see how your heart responds before you ever do it alone.
- One dose per episode. If it has not worked in the expected time, that is when you call, not when you take more.
- Rest afterwards and do not drive for several hours.
Comfort Measures at Home (No Medication Needed)
These simple steps support healing and ease symptoms. Use them alongside any medication your doctor prescribes.
- Learn your own triggers. For many people it is alcohol, poor sleep, dehydration, or a large late meal.
- Keep a simple log of episodes with the date, how long it lasted, and what you were doing.
- Go easy on alcohol. It is one of the most common and most avoidable triggers.
- Treat sleep apnea if you have it. Untreated apnea makes atrial fibrillation much harder to control.
- Stay well hydrated, and keep caffeine at a level you know you tolerate.
- If you use a smartwatch that records rhythm, bring the recordings to your visits.
Related guides from our practice.
Atrial Fibrillation and Atrial Flutter — the rhythms these drugs treat.
Sotalol (Betapace) — the option when the heart is not structurally normal.
Amiodarone — the strongest rhythm drug.
EP Study and Ablation — the procedure alternative.
Beta-Blockers and Calcium Channel Blockers — the rate-slowing pills taken alongside.
Atrial Fibrillation and Atrial Flutter — the rhythms these drugs treat.
Sotalol (Betapace) — the option when the heart is not structurally normal.
Amiodarone — the strongest rhythm drug.
EP Study and Ablation — the procedure alternative.
Beta-Blockers and Calcium Channel Blockers — the rate-slowing pills taken alongside.
Risks, Benefits, and Alternatives
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
Every choice has trade-offs. Use this table to start the shared decision conversation with your care team.
| Option | Risks | Benefits | Alternatives |
|---|---|---|---|
| Flecainide or propafenone | Cannot be used if you have a prior heart attack, a weak pump, or significant coronary disease. Can turn fibrillation into flutter, so a rate-slowing pill is required. Needs periodic ECGs. | Effective at holding a normal rhythm in a structurally normal heart. Can be used as a single dose only when needed. No hospital stay to start in most cases. Available as generics. | Sotalol or dofetilide, which work regardless of heart structure but need a hospital start. Amiodarone. Ablation. Or rate control alone. |
| Sotalol or dofetilide | Both stretch the QT interval, and both are started in the hospital on a monitor. Both are cleared by the kidneys. | Work whether or not the heart is structurally normal, which is the main gap these drugs fill. | Flecainide or propafenone if your heart is structurally normal and you would rather avoid a hospital stay. |
| Amiodarone | The most long-term side effects. Can affect the thyroid, lungs, liver, eyes, and skin, so it needs monitoring of several organs. | The most effective option, and usable when the heart muscle is weak. | Any of the above if your heart allows. Ablation, to avoid long-term drug exposure. |
| Ablation | A procedure with procedural risk. May need repeating. Not everyone is a candidate. | Can reduce or remove the need for rhythm drugs altogether. Often more effective than drugs at keeping a normal rhythm. | Staying on a rhythm drug. Or rate control with no attempt at rhythm control. |
Common Misconceptions
| Myth | Reality |
|---|---|
| The CAST trial means these drugs are dangerous for everyone. | It does not. CAST studied a specific group: people who had already had a heart attack and had a weakened pump. In that group the drug caused harm. In a structurally normal heart, these drugs have a long record of safe use. The lesson was about matching the drug to the heart, not about banning the drug. |
| I can take my pill-in-the-pocket dose the moment I feel anything. | Only after the rate-slowing pill, and only following the plan you were given. Taking the rhythm pill alone is the situation that can produce a very fast heart rate. |
| If one dose does not work, I should take another. | No. One dose per episode. If it has not worked within the time you were told, that is the point to call us or go in, not to take more. |
| The rate-slowing pill is just for symptoms. | It is a safety requirement. It blocks the pathway that would otherwise let the lower chambers follow a flutter beat for beat. |
| My heart was checked years ago, so I am still fine to take this. | Hearts change. A new heart attack, a drop in pump function, or new coronary disease all change the answer. Tell us about any new cardiac event, and expect a repeat echocardiogram from time to time. |
| These drugs thin my blood, so I do not need a blood thinner. | They do not thin the blood at all. Whether you need a blood thinner depends on your stroke risk score, and it is a completely separate decision from rhythm control. |
| If I feel normal, the atrial fibrillation is gone. | Feeling normal is good, but atrial fibrillation can occur without symptoms. That is why we may still monitor, and why the blood-thinner decision does not change just because you feel well. |
Why We Checked Your Heart Before Prescribing
- An echocardiogram shows how well your heart pumps and whether the muscle is thickened or scarred.
- A stress test or a scan of the arteries looks for significant coronary blockages.
- Together these answer the one question that decides whether this drug is safe for you.
- A normal result is genuinely reassuring, and it is what makes these drugs a good option.
- The answer can change over time, which is why we may repeat the echocardiogram.
- If you have a heart attack or are told your pump has weakened, tell us before your next dose.
Possible Complications
Knowing what can go wrong helps you spot problems early. Most complications are uncommon, especially with treatment.
| Where / What | What Can Happen |
|---|---|
| Atrial flutter with 1:1 conduction | The most important one to understand. These drugs can organize fibrillation into flutter, and the lower chambers can then follow beat for beat, with rates approaching 300. It causes severe lightheadedness, fainting, or collapse. The rate-slowing pill is what prevents it. |
| A worse rhythm in a heart with structural disease | This is what CAST showed. It is the reason for the echocardiogram and the restriction, and the reason we ask about any new cardiac event. |
| Slowing of the electrical signal | Both drugs widen the electrical complex on the ECG. We check this periodically, since too much slowing means the dose should come down. |
| Dizziness and blurred vision | Common with flecainide, often early on and often improving. Tell us if it persists or affects your driving. |
| A metallic or bitter taste | Fairly common with propafenone. Harmless, but a frequent reason people ask to switch. |
| Worsening asthma or wheezing | Propafenone has mild beta-blocking effects and can tighten the airways. Tell us if you have asthma. |
Points to Know
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you remember nothing else, remember these key points.
- These drugs are for a structurally normal heart. That is the single most important rule, and it is why you had an echocardiogram first.
- Always take the rate-slowing pill alongside. It is a safety requirement, not an optional extra.
- For pill-in-the-pocket: rate-slowing pill first, wait about 30 minutes, then one dose of the rhythm pill.
- One dose per episode. Never a second dose because the first has not worked yet.
- After you treat an episode, rest and do not drive for the next several hours.
- Tell us about any new heart attack, new chest pain, or any drop in your pump function. It changes whether this drug is still right for you.
- These do not thin your blood. Your blood-thinner decision is separate and is based on your stroke risk.
- Bring smartwatch rhythm recordings to your visits if you have them.
When to Call Us — and When to Call 911
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you are not sure, call. We would rather hear from you twice than miss a real problem.
- Fainting, or nearly fainting. Call 911.
- A very fast heartbeat that comes with chest pain, severe breathlessness, or confusion. Call 911.
- A racing heart after taking a pill-in-the-pocket dose that feels worse rather than better. Call 911.
- An episode that has not stopped within the time you were told to expect. Call us the same day.
- New chest pain or pressure with activity. Call us the same day, since this can change whether the drug is safe for you.
- Persistent dizziness or blurred vision. Call us this week.
- New wheezing or shortness of breath. Call us this week.
- Before starting any new medicine, and before any procedure. Call us first.
Office: (727) 943-5200
Trusted Resources
Independent, evidence-based pages we recommend for deeper reading.
- MedlinePlus (NIH) — Flecainide — NIH plain-language drug facts for flecainide.
- MedlinePlus (NIH) — Propafenone — NIH plain-language drug facts for propafenone.
- Cleveland Clinic — Atrial Fibrillation — Background on the rhythm these drugs are used to treat.
- American Heart Association — Treatment of Arrhythmia — How rhythm drugs compare with procedures.
Sources Used to Build This Guide
- Cardiac Arrhythmia Suppression Trial (CAST) — Echt DS et al., N Engl J Med 1991 [primary_trial] — The trial that established the structural-heart-disease restriction: increased mortality with flecainide in patients after a heart attack with reduced ejection fraction. This is the single most important safety fact in the guide.
- Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation — JACC Clinical Electrophysiology [peer_reviewed] — Source for the pill-in-the-pocket weight-based dosing and the requirement that the first dose be supervised.
- Pill-in-the-Pocket for Paroxysmal Atrial Fibrillation: A Review and Case Study [peer_reviewed] — Source for the AV-nodal-blocker-first sequence, the 30-minute interval, and the weight cutoff at 70 kg.
- Atrial flutter with flecainide-induced 1:1 conduction — European Heart Journal Case Reports [case_report] — Documents the 1:1 atrial flutter conduction hazard that makes the AV nodal blocker mandatory, used for the warning callout.
- Flecainide use in arrhythmic patients who have structural heart disease [peer_reviewed] — Contemporary reappraisal of CAST; cited for the honest note that the restriction is being re-examined in selected patients but remains the standard of care.
- MedlinePlus (NIH) — Flecainide [patient_education] — NIH plain-language drug facts for flecainide.
- MedlinePlus (NIH) — Propafenone [patient_education] — NIH plain-language drug facts for propafenone.
- Cleveland Clinic — Atrial Fibrillation [patient_education] — Patient-voice framing for rhythm control versus rate control in atrial fibrillation.
